Morgan Stanley recently met with Nvidia's management team. Here are the biggest takeaways as the bank eyes another 12% upside for the stock.
Nvidia's Blackwell GPU chips are sold out for the next 12 months, Morgan Stanley said after hosting CEO Jensen Huang and CFO ...
Equinor upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Equinor to Equal Weight from Underweight with a $25.80 price target The firm maintains a cautious ...
Morgan Stanley Sees Brazil Stock Gloom Despite Growth Pickup
Brazil’s economy is growing faster than expected and stocks are cheap, said Morgan Stanley strategist Nikolaj Lippmann. Just ...
3 reasons the dollar can't be dethroned as the world's dominant currency, according to Morgan Stanley
De-dollarization efforts won't do much to dethrone the dollar, Morgan Stanley said.  There are no true alternatives to ...
Morgan Stanley Boosts Wynn Resorts (NASDAQ:WYNN) Price Target to $112.00
Wynn Resorts (NASDAQ:WYNN – Get Free Report) had its price target lifted by investment analysts at Morgan Stanley from ...
Morgan Stanley Thinks Blackwell Chips Could Generate $10 Billion in Sales for Nvidia by Q4. Here's 1 Other Figure I'm More Interested to See.
Nvidia's stock price may not see a significant boost given high valuation multiples, unless there are positive signs from ...
Why Morgan Stanley Shares Are Rising
Morgan Stanley shares are trading higher by 2.8% Friday afternoon. The stock is gaining following stronger-than-expected ...
New Morgan Stanley headquarters to be built in Homewood
Work has begun on a new 30,000-square-foot office building headquarters for Morgan Stanley in Homewood. Brmingham-based ...
bovnews17h
Why Did Morgan Stanley Give Rockwell Automation Inc (ROK) Stock Overweight Rating?
On Friday, Rockwell Automation Inc (ROK) stock saw a modest uptick, ending the day at $271.16 which represents a slight increase of $3.01 or 1.12% from the prior close of $268.15. The stock opened at ...
Think Advisor3d
FINRA Bars Former Morgan Stanley Advisor
Robert Daly declined to provide information for a probe related to possible undisclosed private securities transactions, ...
Morgan Stanley Remains a Sell on Y-Mabs Therapeutics (YMAB)
In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on Y-Mabs Therapeutics (YMAB – Research Report), ...
Morgan Stanley Sticks to Their Hold Rating for United Therapeutics (UTHR)
Morgan Stanley analyst Terence Flynn maintained a Hold rating on United Therapeutics (UTHR – Research Report) today and set a price ...